UK Public Sector Contracts & Tenders

Urgent award - PSR<br/>Being awarded to incumbent provider and will procure next year <br/>SWLP shall provide a comprehensive diagnostic pathology service for specimens received from the Purchaser.

The procurement of a next-generation sequencing (NGS)–based test assay designed for the detection and monitoring of minimal residual disease (MRD) in patients with certain haematologic malignancies, such as multiple myeloma, acute lymphoblastic leukaemia (ALL), and chronic lymphocytic leukaemia (CLL). The required goods and services include: • Provision of assay kits and reagents suitable for the intended patient population. • Use of a software platform for analysis and reporting of results. • Training and technical support for laboratory and clinical staff to ensure accurate sample processing, data interpretation, and integration into clinical workflows. • Ongoing technical support, maintenance, and updates for both hardware (if applicable) and software components. • Delivery of consumables and reagents on a schedule that aligns with clinical demand, ensuring continuity of patient testing. • Compliance with all relevant regulatory standards (e.g., CE-IVD, UKCA marking) and data protection requirements for patient information. • Optional: Integration with existing laboratory information management systems (LIMS) and electronic health records (EHR), if required. • MRD sensitivity threshold of 10-5 or lower • Must work on DNA • Performance data must be supported by evidence generated in relevant disease specific Clinical Trials • Recognised technology included in clinical guidelines • Ability to track clonal evolution

The Cyberknife machine and planning system service contract have to be provided by Accuray<br/>(the manufacturer of the equipment and associated software) as it is bespoke, extremely<br/>specialist equipment manufactured by Accuray. There is no other company that can provide<br/>the CE marked replacement parts, software upgrades and bug fixes, whose engineers are<br/>trained on the specific maintenance of this equipment in order to plan and deliver radiation<br/>safely and correctly to the patient.

The Trust had to purchase software and service for the Elekta Machines. The whole system consists of a linear<br/>accelerator and a MR subsystem. The The Machines below needs to be maintained according to the manufacturer’s<br/>specification to be able to treat patients:<br/>Synergy<br/>Versa HD<br/>Juniper Synergy<br/>Unity <br/>Clarity ICR<br/>ABC 3 <br/>SM00076639<br/>SM00076640<br/>The only company which provides the maintenance service and spare<br/>parts in case of a breakdown is Elekta. No other company can provide support for the system in line with the<br/>medical device regulations.<br/>Duration of the above contract is 5 years.

Provision of independent Lifts Authorising Engineer services, including statutory compliance assurance, technical advice, inspection oversight, certification review, and support to ensure safe operation and compliance with relevant legislation and standards across the Trust’s estate.

PSMA kit is used as a diagnostic tool, when radiolabelled with Gallium 68 radioisotope, in prostate cancer.

The procurement of a next-generation sequencing (NGS)–based test assay designed for the detection and monitoring of minimal residual disease (MRD) in patients with certain haematologic malignancies, such as multiple myeloma, acute lymphoblastic leukaemia (ALL), and chronic lymphocytic leukaemia (CLL). The required goods and services include: • Provision of assay kits and reagents suitable for the intended patient population. • Use of a software platform for analysis and reporting of results. • Training and technical support for laboratory and clinical staff to ensure accurate sample processing, data interpretation, and integration into clinical workflows. • Ongoing technical support, maintenance, and updates for both hardware (if applicable) and software components. • Delivery of consumables and reagents on a schedule that aligns with clinical demand, ensuring continuity of patient testing. • Compliance with all relevant regulatory standards (e.g., CE-IVD, UKCA marking) and data protection requirements for patient information. • Optional: Integration with existing laboratory information management systems (LIMS) and electronic health records (EHR), if required. • MRD sensitivity threshold of 10-5 or lower • Must work on DNA • Performance data must be supported by evidence generated in relevant disease specific Clinical Trials • Recognised technology included in clinical guidelines • Ability to track clonal evolution

The Laboratory at RMH is currently using these DNA adaptors for high throughput sequencing experiments. These reagents are required to deliver a service. The adaptors have been validated for tests that RMH offers as part of the Molecular Diagnostic service and are incorporated into Standard Operating Procedures.

A recommendation by the difficult airway society for an alternative scope to be used for awake fibreoptic intubations at Royal Marsden Hospital, has resulted in the swap of the current used scopes to the C-Mac Five s Scopes provide only by Storz. The unique proposed alternative scope has a 3.5mm in diameter, with 180/180-degree deflection has the unique ability to utilise a size 4 ET tube, which means a different cohort of patients which isn’t currently possible due to its narrower diameter (smaller patients), In addition 65cm scope length gives the ability for the clinician to look further into the lungs. This length is also unique to Storz scopes compare to a standard 60cm scopes. The number of scopes use by the Trust per year allow the Trust to have 7 CMAC screens unique to Storz free of charge which will allow to perform video laryngoscope and awake fibreoptic intubations in the same screen, which will improve the quality visualisation of Head and Neck, and non-head and neck.

The Laboratory at RMH is currently using these DNA adaptors for high throughput sequencing experiments. These reagents are required to deliver a service. The adaptors have been validated for tests that RMH offers as part of the Molecular Diagnostic service and are incorporated into Standard Operating Procedures.

The Laboratory at RMH is currently using these DNA adaptors for high throughput sequencing experiments. These reagents are required to deliver a service. The adaptors have been validated for tests that RMH offers as part of the Molecular Diagnostic service and are incorporated into Standard Operating Procedures.

Koelis Trinity biopsy Systems

The provision of 12 Trust standard scalp cooling devices for the OCC RMH

The Guardant360 assay kits are required to deliver the Trust's partnership agreement with Guardant Health. This is the only kit that can be used to deliver this and is included in the contract requirements with Guardant.

.The Royal Marsden Hospital requires purchase of ANMI PSMA Setrile 360 VIALS and ANMI Elution Tools Gen A to treat prostate cancer. ANMI PSMA Setrile 360 Vials and ANMI Elution Tools Gen A is the only viable kit for imaging of prostate cancer, disease progression or staging of cancer in UK. There is no licensed product in the UK at the moment, XIEL is the only official UK Distributor of the ANMI HBEDCC-11 PSMA Kit and follows the Regulated Import Pathway approved by the MHRA for this product.

Contract for Netspot Kits required by the trust

Direct Award A - single source

for the the supply of paediatric bone marrow harvests- a highly specialist procedure that’s conducted in a limited number of Trusts within the UK for our cohort of Paediatric patients (under 12KG), under 5 other UK Trusts.